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Abstract 
Background 
Bariatric surgery markedly reduces fat mass with beneficial effects on cardiometabolic 
health but the mechanisms involved are not fully understood. Extracellular vesicles (EVs) are 
secreted by a variety of cells, including adipocytes, and may mediate some of these benefits. 
However, the effects of bariatric surgery on circulating EVs are unclear. 
Methods 
Concentration of plasma EVs isolated by ultracentrifugation at baseline, 1- and 6 months 
post-bariatric surgery (n=20)  was established using Nanoparticle Tracking Analysis. EV origin 
(CD9: exosome; CD41: platelet; CD235a: erythrocyte; CD11b: leukocyte; CD144: 
endothelial), cytokine (interferon ɤ, interleukin-6, TNFα) and adipocyte marker (adiponectin, 
FABP4, PPARɤ) expression was measured by Time Resolved Fluorescence immunoassay. 
Results 
EV concentration and cell-of-origin markers (CD41, CD235a, CD11b, CD144) did not alter in 
response to surgery, neither did EV-expressed interferonϒ, IL-6, TNFα, adiponectin, PPARϒ 
or CD9.  EV-derived Fatty Acid Binding Protein 4 (FABP4) increased at 1 month (+49%) 
before returning to baseline by 6 months (-51%, p<0.05), corresponding to similar changes 
in circulating plasma FABP4 (+22% and -24% at 1- and 6-months, respectively; p<0.001)). 
Patients who underwent biliopancreatic diversion had lower FABP4-expressing EVs at 6 
months compared to those who underwent sleeve gastrectomy/gastric banding (p<0.05), 
despite similar percentage weight reduction (-19% vs -20%, respectively). CD9 expression 
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correlated with EV-expressed FABP4, adiponectin, TNFα and Interferon ϒ (r=0.5, r=0.59, 
r=0.53, r=0.41 respectively, p<0.005), suggesting transport by an EV population of exosomal 
rather than microvesicular origin.    
 
Conclusions 
Bariatric surgery leads to a transient change in circulating EV- and plasma-derived FABP4, 
reflecting alterations in adipose tissue homeostasis. 
 
 
Introduction 
The obesity pandemic has led to a greater adoption of bariatric surgery as a treatment for 
morbid obesity and its secondary complications [1]. Bariatric surgery exerts multiple effects 
on adipose tissue [2], including reduced adipocyte size, improved sensitivity to insulin,  
increased adiponectin and decreased levels of leptin, CRP, IL-6, TNFα and Monocyte 
Chemoattractant Protein-1 (MCP-1)[2]. However, the pathways regulating these changes 
are not fully understood.  
 
Extracellular vesicles (EVs) are submicron particles secreted by most cell types during the 
cell cycle and particularly during cell stress [3,4]. EVs are released in one of two ways: 
intracellular formation of multivesicular exosomes which are subsequently released from 
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the plasma membrane, or as microvesicles (MVs) that are released directly from plasma 
membrane budding [3,4]. They contain cytoplasmic and membrane components of their 
‘donor’ cell such as enzymes, proteins and microRNA [4]  and are believed to affect recipient 
cell biology and gene transcription. EVs have also emerged as potential disease biomarkers 
[5]. Adipocyte-derived EVs (AD-EVs) are likely to play important roles in paracrine and 
endocrine communication within adipose tissue but comparatively little is known about 
them. They probably represent only a small percentage of the total population of EVs 
present in the circulation [6,7] , at least in the healthy state, but are known to affect target 
cell activity [8,9], including increased lipid storage in small adipocytes[10].   
Fatty Acid Binding Protein 4 (FABP4) is one of the most abundant cytoplasmic proteins 
within adipocytes, whose function extends beyond lipid transport to include regulation of 
glucose metabolism and inflammatory responses [6,11]. Recent data in 3T3-L1 adipocytes 
and mouse adipose tissue demonstrate that lipolytic stimuli trigger accumulation of FABP4 
within intracellular multivesicular bodies (MVB), and its subsequent secretion via the non-
classical pathway in vesicles expressing exosomal markers (CD63 and ALG-2 interacting 
protein X(ALIX))[7]. It appears, however, that only a small proportion of total FABP4 is 
transported in this way [6,7].  
Since lipolysis triggers EV secretion from adipocytes, conditions associated with substantial 
weight loss might result in increased secretion of adipocyte-derived EVs into the circulation. 
We therefore hypothesised that bariatric surgery would result in increased expression of 
adipocyte-derived proteins, including FABP4, not only in a free form but also in association 
with EVs.  
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Methods 
Study populations 
EV characterisation was undertaken at 3 time-points in 20 patients undergoing elective 
bariatric surgery at The Welsh Institute of Metabolic and Obesity Surgery (WIMOS), 
Swansea, UK.  Patients were aged 20-60 years and had a body mass index (BMI) >40kg/m2. 
All subjects had type 2 diabetes (T2DM) or impaired glucose tolerance (IGT), diagnosed 
during an oral 75g glucose tolerance test (OGTT)[12] . Patients with any acute concurrent 
illness were excluded. Thirteen of the patients underwent restrictive laparoscopic surgery 
(sleeve gastrectomy (SG) n=10, gastric banding (GB) n=3) and seven an open malabsorptive 
procedure (biliopancreatic diversion (BPD)).  
Sample preparation 
Fasting venous blood was collected from a large peripheral vein into EDTA vacutainers. 
Samples were immediately spun twice at 3000g for 10mins to render plasma acellular, then 
frozen and stored at -80°C until further analysis.  
EV isolation and characterisation 
In order to isolate EVs, acellular plasma underwent 100,000g ultracentrifugation at 4˚C for 1 
hour. EVs were then re-suspended in 1x sterile phosphate-buffered saline (PBS) (0.22µm 
filtered). EV size and concentration were established by nanoparticle tracking analysis (NTA) 
using Nanosight LM10 (Malvern, UK), software version 3.1. For each sample, 60 second 
videos were recorded in replicates of 5. NTA determines the size and concentration of EVs 
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by analysing the Brownian motion and light scattering properties of the nanoparticle 
suspension illuminated by a laser beam [13]. 
Time Resolved Fluorescence (TRF) immunoassay [14,15] was used to establish EV cellular 
origin, cytokine and adipocyte-marker expression (CD41, CD11b, CD235a, CD144, CD9, IL-6, 
TNFα, interferon ɤ, adiponectin, FABP4; supplementary material).    
Other assays 
 Fasting glucose was measured using a Roche Modular P800 Analyser. A Roche Modular 
E170 was used to measure fasting insulin. High sensitivity ELISA kits were used to evaluate 
IL-6 concentration (R&D Systems, Minneapolis, MN, USA). Plasma FABP4 concentration was 
established using a human FABP4 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, 
USA) and plasma free fatty acids were measured by a Colorimetric Quantification Assay Kit 
(ab65341, Abcam, Cambridge, UK). All samples were assayed in duplicate. 
Statistical analysis  
This was a proof of concept study that had the primary aim of determining the change in 
plasma- and EV-expressed FABP4. There are very limited data available in relation to FABP4 
in plasma following bariatric surgery and, to our knowledge, no studies investigating EV 
FABP4 in this context. As we anticipated a 20% change in plasma FABP4 over the three 
sampling points and a range of 10-15%, a power calculation suggested that we would need 
at least 15 subjects to detect this difference (one-way ANOVA at 3 levels; p=0.05; 
alpha=0.8).  
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Normally distributed variables were reported as mean ± SD whereas non-normally 
distributed variables were summarised as medians with interquartile ranges (IQR). For 
normally distributed variables the differences at different time points were analysed using 
repeated measured ANOVA with Bonferroni’s multiple comparisons post-test analysis. For 
changes in variables with non-Gaussian distribution, the Kruskall-Wallis test was applied 
with post-test Dunn’s comparison. Spearman’s correlation analysis was applied to detect 
significant correlations between evaluated parameters. Statistical significance was accepted 
at p<0.05 and Graph Pad version 6.0 was used.  
 
Results 
Population characteristics 
There were thirteen female and seven male patients, with a mean age of 50.7±8 years and a 
baseline mean body weight and BMI of 151.3 ± 31 kg and 54 ± 12.6 kg/m2, respectively. The 
anthropometric and metabolic characteristics are summarised in Table 1. As anticipated, all 
patients undergoing bariatric surgery achieved significant total weight loss (TWL) ( -8.3% at 
1 month and -20% at 6 months to mean values of 138.8 kg and 121.6 kg, respectively; 
p<0.001) and BMI reduction of -10% and -18.5% (to mean values of 48.9 ± 11 and 44 ± 10.2 
kg/m2, respectively; p<0.001). 
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EV concentration and content  
There were no significant differences in mean EV concentration/mL of plasma between 
baseline (1.44 ± 0.9x1011 nanoparticles/mL), 1 month (1.3 ± 0.7 x1011) and 6 months 
postoperatively (1 ± 0.4x1011) (Figure 1a). However, detailed analysis of EV concentration 
within different size ranges (measured every 100nm) revealed a significant reduction in EVs 
measuring between 100 and 200nm in diameter at 6 months compared to baseline 
(p<0.001) (Figure 1b).  
The relative distribution of the main EV cell-of-origin markers (CD41 (platelets), CD11b 
(monocytes/macrophages), CD235a (erythrocytes), CD144 (endothelial cells)) did not 
change in response to surgery (Figure 2).  
Following surgery, there were no differences in median TRF signal for the exosomal marker 
CD9, EV-expressed adiponectin, PPARɤ, IL6, TNFα or interferon ϒ (data not shown).  
However, the FABP4 EV signal increased (non-significantly) at 1 month before falling 
significantly by 6 months (p<0.01) (Figure 3a, 3b). The  FABP4 EV signal at 6 months’ follow-
up was significantly lower in the group who underwent biliopancreatic diversion surgery 
(n=7) compared to those who had sleeve gastrectomy or gastric banding (n=13) (p<0.05) 
(Figure 3c), with no differences in EV FABP4 expression between those groups at baseline or 
1 month.  
A highly significant correlation was observed between the EV signal for CD9 and each of 
FABP4 (r=0.5, p<0.0005), adiponectin (r=0.59, p<0.0001), TNF-α (r=0.53, p<0.0001) and 
interferon ɣ (r=0.41, p<0.005) (Figures 3d-g), suggesting that these adipocytokines are 
transported by an EV population which is specifically of exosomal origin. 
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A similar pattern of change to that observed for EV FABP4 was observed with free plasma 
FABP4, with a significant rise at 1 month (p<0.001 vs baseline) before a significant decrease 
by month 6 (p<0.001 vs month 1) (Figure 4a, 4b).  Furthermore, we observed that plasma 
FABP4 concentration correlated with plasma free fatty acid concentration at 1 month 
follow-up (r=0.48, p<0.05) but not at baseline or 6 months. Neither BMI nor plasma FABP4 
correlated with EV FABP4 (Figure 4c, 4d).  
In order to explore any relationship between EVs and weight loss, we subsequently 
subdivided our sample into two similar-sized groups: those who achieved more than 18% 
TWL at 6 months (n-9) and those who did not (n=11). Two significant differences were 
observed: significantly lower EV PPARϒ in the group that achieved greater weight loss at 6 
months’ follow-up, and significantly higher EV TNFα at 1 month follow-up in the group that 
failed to achieve weight loss of >18%. In contrast, no relationships between any EV changes 
and improvements in glucose metabolism were observed (data not shown). 
Since differences in fat distribution and lipolysis between men and women have been 
described [16], we also analysed our data split by gender. There were no gender differences 
in FFA concentrations at any time-point. Plasma FABP4 concentration at 6 months’ follow-
up was higher in females (78.47±14.9 vs 48.27±21 ng/mL, p<0.05) despite no significant EV 
FABP4 or BMI differences between genders at this time-point. EV CD11b 
(monocyte/macrophages marker) was higher in females at all time-points (p<0.05). Baseline 
EV PPARϒ was also higher in females (p<0.05); however, no differences were observed post-
surgery. No other differences were observed in other EV markers. 
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Discussion 
Our study shows that bariatric surgery is followed by dynamic changes in the expression of 
EV-associated as well as free plasma FABP4. Since FABP4 is predominantly expressed in 
adipocytes, our finding of altered EV-expressed FABP4 after surgery is likely to reflect 
changes in adipocyte EV secretion.   As demonstrated by Ertunc et al, lipolysis triggers a non-
classical pathway of FABP4 secretion within EVs, and these EVs may be intended to play a 
different role in intercellular communication compared to their free circulating form [7]. 
Bariatric surgery is known to rapidly reduce visceral and subcutaneous lipid depots, 
accompanied by an increase in plasma free fatty acids and beta-hydroxybutyrate levels, 
reflecting increased lipolysis [17]. Previously, increased expression of lipolytic genes within 
adipose tissue following bariatric intervention was demonstrated, including triglyceride 
lipase (ATGL), hormone-sensitive lipase (HSL) and perilipin [18]. ATGL, HSL and free fatty 
acids have been found to affect FABP4 secretion [7].  
In our study, EVs expressing FABP4 and plasma free FABP4 showed a similar pattern of 
change with a transient peak in the early postoperative period followed by significant 
reduction at 6 months’ follow-up compared to 1 month. Furthermore, plasma FABP4 levels 
at 1 month correlated with plasma free fatty acid levels. We therefore believe that the 
transient postoperative rise in EV and plasma FABP4 may reflect the dynamic changes 
occurring in adipose tissue following surgery, including reduced total fat mass and adipocyte 
size, and increased lipolysis, albeit that a limitation of our work is that we did not measure 
plasma glycerol. Previous studies have shown similar changes in circulating FABP4 levels 
following weight loss [19, 20]. Stejskal et al indicated that this pattern of an initial rise in 
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plasma FABP4 with subsequent normalisation to baseline levels was observed particularly in 
individuals who achieved sustained weight loss [21]. However, we are unaware of any 
previous study evaluating EV-expressed and plasma free FABP4 simultaneously in the 
context of bariatric surgery.   
Open bariatric surgery might involve more adipose tissue damage compared to a 
laparoscopic approach. However, at 1 month follow-up we did not observe differences in 
plasma and EV FABP4 in the BPD group compared to the SG/GB group. Nevertheless, it is 
entirely possible that differences in plasma- and EV-FABP4 between open and laparoscopic 
surgery might be apparent at very early time-points post-surgery.   
We did not find a correlation between plasma FABP4 and the EV FABP4 TRF signal, nor 
between EV FABP4 and BMI. This might relate to the fact that adipocyte-derived FABP4-
containing EVs probably carry only a small proportion of the total FABP4 secreted by 
adipocytes [6,7]. Moreover, adipocyte-derived EVs containing FABP4 could also be taken up 
by neighbouring cells in adipose tissue in a paracrine manner, as shown in previous studies 
[10]. Therefore, establishing a correlation between BMI and both plasma soluble FABP4 and 
EV-contained FABP4 is difficult. In contrast, EV-expressed TNFα was greatest at 1 month in 
subjects showing less weight loss. Whilst mechanisms other than weight loss may contribute 
to the changes in EV FABP4, it is tempting to speculate that EVs in patients showing the 
greatest weight loss exhibit a reduced inflammatory profile. However, this remains to be 
fully elucidated.  
Previous studies examining the effects of bariatric surgery on circulating EVs have largely 
focused on changes in EV concentration and cell-of-origin expression, such as platelets, 
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monocytes or endothelial cells. Campello et al  evaluated changes in a range of EV subtypes 
in 20 patients undergoing sleeve gastrectomy and found a significant decline in endothelial-, 
platelet-, and leukocyte-derived EVs and in annexin V, tissue factor and CD36-expressing EVs 
at 12 months’ follow-up [22]. The percentage reduction in EV subtypes correlated with the 
reduction in BMI. Similarly, Cheng et al found a reduction in platelet-, endothelial-, 
monocyte- and tissue factor-expressing EVs in patients following Roux-en-Y gastric bypass 
surgery, with the monocyte EVs showing an association with HbA1c and BMI reductions 
[23].  In contrast, Stepanian et al  found no effect of significant weight loss (mean BMI 
decrease of 24%, n=32, including 27 patients who had gastric bypass or sleeve gastrectomy) 
on total-, platelet- or endothelial-derived EVs, despite improvements in HOMA-IR, lipid 
profile and CRP [24]. This is in keeping with our findings, since we found no effect on 
platelet, leukocyte, erythrocyte or endothelial EVs nor overall EV concentration irrespective 
of the type of bariatric surgery performed and despite improvements in weight and 
glycaemic control. However, it should be noted that all of these referenced studies used 
flow cytometry to evaluate EV concentration and origin/protein expression. This approach is 
not sensitive enough to distinguish between different populations of EVs and to detect very 
small EVs (<200nm), as the analysis gate in standard flow cytometers is usually determined 
using 1µm beads. Therefore, the exosomal EV range which showed very interesting 
biological correlation in our data cannot be fully evaluated using flow cytometry alone.  
Identification of more precise changes pertaining to adipobiology that take place following 
the surgical approach are in line with the usefulness of new criteria to define success of 
bariatric and metabolic surgery that are being put forward.[25] 
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Similar to previous research evaluating EV changes post-bariatric surgery, the main 
limitation of our study includes the relatively small sample size. The study may therefore be 
underpowered to show significant differences in other EV cytokines. Secondly, many of our 
patients were taking concomitant medications at the time of study enrolment, including 
diabetes medication as, in contrast to most previous studies, we did not exclude patients 
with chronic illnesses such as hypertension or dyslipidaemia, which could have interfered 
with the EV readings. Thirdly, our study had a relatively short follow-up; studies with a 
longer follow-up period are needed in the future to fully describe the chronic changes in EVs 
post-bariatric surgery. Fourthly, it would have been helpful to have included a control group 
of patients undergoing non-bariatric surgery for comparison. Lastly, direct comparisons 
between clinical studies evaluating changes in circulating EVs are limited by the fact that 
establishing a gold standard method for EV isolation to be adopted across laboratories has 
only recently been a focus of the International Society of Extracellular Vesicles (ISEV) [26], 
although our adopted approach is one of the most commonly accepted protocols that we 
have introduced to yield consistent samples and results. This approach was not used in the 
studies by other authors [22-24] and similarly the EV analysis in the studies we cited was 
performed by flow cytometry which is typically not sensitive enough to detect EVs of 
exosomal origin and differs from our immunophenotyping method which we adapted for EV 
analysis specifically [14,15]. 
Despite the significant weight loss achieved by all study participants, the average 6 months’ 
follow-up BMI remained within the class III obesity range (Table 1) which may partially 
explain why no significant differences in more of the EV markers were observed and why 
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the baseline and 6 months' follow-up plasma and EV-FABP4 results did not differ.  
Individuals who were selected to undergo BPD surgery had a higher average BMI at all 3 
time-points compared to the SG/GB cohort, which corresponded with equally higher 
concentration of plasma FABP4 in this group (p<0.05). Interestingly, however, the 6 months’ 
follow-up EV FABP4 signal was significantly lower in the BPD arm compared to the SG/GB 
one, despite no differences at baseline or 1 month follow-up between these groups. Given 
that FABP4-expressing EVs are likely to derive from adipocytes, this may suggest that BPD 
has a greater effect on postoperative processes within adipose tissue regulating the 
secretion of this group of EVs. Although the mechanism behind this and the biological 
relevance of this phenomenon is not clear at present, this finding may be in keeping with 
previous reports indicating that this form of metabolic surgery might be more effective in 
reversing obesity-driven comorbidities such as type 2 diabetes, hypertension and 
dyslipidaemia[27,28]. Finally it should be noted that although increased circulating 
adipocyte-derived EVs suggest disturbed adipose tissue homeostasis, their full biological 
role has not been fully investigated and they may, depending on clinical circumstances, play 
a deleterious as well as protective role, as has been recently shown for circulating 
endothelial EVs in the context of vascular disease [29]. 
 
Conclusion 
To our knowledge, this study is the first to report concomitant fluctuations in plasma free 
FABP4 in addition to exosome-associated FABP4 secretion in the follow-up period after 
bariatric surgery which may relate, at least in part, to increased lipolysis. These changes are 
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likely to play an important role both in paracrine communication within adipose tissue and 
endocrine communication with other target tissues, since EVs are able to affect recipient 
cells’ function and gene expression. Our observations suggest that adipocyte-derived EVs 
may be regarded as potential markers of adipose tissue health, and could represent a target 
for novel therapies aimed at improving metabolic health. However, further research is 
required in order to understand the precise mechanisms regulating secretion and content of 
adipocyte-derived EVs. 
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Figure 1: a) EV concentration/mL of plasma at baseline, 1 month and 6 month follow-up 
(mean±SEM) b) 2-way ANOVA with Bonferroni post-test revealed significant decrease in EVs 
sized 100.5-199.5nm in diameter at 6 months’ follow-up compared to baseline (mean±SD), 
p<0.01 (**) 
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Figure 2: Bariatric surgery did not alter EV cellular origin. Relative expression at baseline, 1 
and 6 months’ postoperatively: CD41 (platelets): 25±13% vs 27±20% and 27±17%; CD11b 
(macrophages/monocytes): 51± 25% vs 51±26% and 54±24%; CD235a (erythrocytes): 10±6% 
vs 11±10% and 9±5%; CD144 (endothelial cells):  15±10% vs 16±12% and 15±13%, 
respectively,  all p=non-significant.  
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Figure 3: a) Changes in EV FABP4 (median with IQR) reveal significantly lower TRF signal at 6 
months’ follow-up compared to 1 month (p<0.05) b) Individual pattern of changes in EV 
FABP4 TRF signal for all study participants at 3 time points c) Median EV FABP4 signal was 
significantly lower in the cohort that underwent biliopancreatic bypass diversion surgery at 
6 month follow-up (p<0.05). Spearman’s correlation analysis revealed significant correlation 
between the exosomal marker CD9 and EV-derived: FABP4 (d), adiponectin (e), TNFα (f) and 
interferon ϒ (g). *=p<0.05, **= p<0.01 
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Figure 4: a) Plasma free FABP4 levels (means) were significantly higher at 1 month follow-up 
compared to baseline and 6 months’ follow-up b) Plasma FABP4 concentration at 3 time 
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points for all study participants (n=20) c) Spearman’s correlation analysis revealed 
significant correlation between plasma FABP4 and BMI (r=0.6, p<0.0001) d) No correlation 
between EV-contained and plasma free FABP4 was observed (r=0.05, p=ns) e) Significant 
correlation was observed between plasma FABP4 and plasma free fatty acids at 1 month 
follow up (r=0.48, p<0.05).  *=p<0.05, **= p<0.01, ***=p<0.001 
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 Baseline  
(n=20) 
1 month  
post-surgery  
P  
(vs. baseline) 
6 months  
post-surgery 
P 
(vs. baseline) 
Age (years) 50.7 (8)     
Gender (M/F) M=7, F=13     
Weight (kg) 151.3 (31) 138.8 (28) <0.001 121.6 (26) <0.001 
BMI (kg/m2) 54 (12.6) 48.9 (11) <0.001 44 (10.2) <0.001 
Glucose (mmol/L) 
IGT subgroup 
T2DM subgroup 
7.9 (3.2) 
5.8 (0.7) 
9.9 (3.4) 
6.2 (1.5) 
5.5 (1.2) 
6.9 (1.6) 
<0.05 
ns 
<0.05 
6.1 (3.0) 
6.1 (4.2) 
6.2 (1.2) 
0.092 
<0.05 
<0.001 
Insulin (mIU/L) 
IGT subgroup 
T2DM subgroup 
111.7 (74.7) 
104.4 (52.5) 
119 (95) 
103.3 (76.5) 
106.2 (72.9) 
100.5 (84.1) 
ns 
ns 
ns 
74.7 (57.5) 
79.3 (67.6) 
69.7 (47.4) 
0.054 
ns 
0.054 
HOMA-IR 
IGT subgroup 
T2DM subgroup 
2.40 (1.37) 
2.25 (0.7) 
2.5 (1.8) 
1.97 (1.36) 
2 (1.4) 
1.9 (1.3) 
ns 
ns 
ns 
1.60 (1.68) 
1.8 (2.1) 
1.37 (0.9) 
<0.001 
ns 
<0.05 
IL-6 (ng/mL) 9.5 (8.3) 11.1 (11.3) ns 14.7 (24.6) ns 
FABP4 (ng/mL) 67.8 (18.5) 
 
 
82.7 (17.7) 
 
 
<0.05 62.7 (19.9) 
 
 
ns 
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Table 1: Anthropometric and metabolic characteristics of patients undergoing bariatric surgery at 
baseline, 1- and 6-months’ follow-up. ns=non-significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
References 
1. Batterham RL, Cummings DE. Mechanisms of Diabetes Improvement Following 
Bariatric/Metabolic Surgery. Diabetes Care 2016 Jun;39(6):893-901. doi: 
10.2337/dc16-0145 
2. Frikke-Schmidt H, O'Rourke RW, Lumeng CN, Sandoval DA, Seeley RJ. Does bariatric 
surgery improve adipose tissue function? Obes Rev. 2016 Sep;17(9):795-809. doi: 
10.1111/obr.12429. Epub 2016 Jun 8. Review. 
3. Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI et al. Biological 
properties of extracellular vesicles and their physiological functions. J Extracell 
Vesicles 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015 
4. Van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, 
and clinical relevance of extracellular vesicles. Pharmacol Rev 2012 Jul;64(3):676–
705 
5.  Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, 
Leftheriotis G et al.  Endothelial function caused by circulating microparticles from 
patients with metabolic syndrome. Am J Pathol 2008;173:1210-9. 
6. Hotamisligil GS, Bernlohr D. Metabolic functions of FABPs- mechanisms and 
therapeutic implications. Nat Rev Endocrinol.  2015 Oct;11(10):592-605. doi: 
10.1038/nrendo.2015.122. Epub 2015 Aug 11. 
26 
 
7. Ertunc ME, Sikkeland J, Fenaroli F, Griffiths G, Daniels MP, Cao H et al. Secretion of 
fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in 
response to adipocyte lipase activity. J Lipid Res. 2015 Feb;56(2):423-34. doi: 
10.1194/jlr.M055798. Epub 2014 Dec 22 
8. Ogawa R, Tanaka C, Sato M, Nagasaki H, Sugimura K, Okumura K et al. Adipocyte-
derived microvesicles contain RNA that is transported into macrophages and might 
be secreted into blood circulation. Biochem Biophys Res Commun. 2010;398(4):723–
9. doi:10.1016/j.bbrc.2010.07.008.76. doi:10.1210/en.2009-1023. 
9. Aoki N, Yokoyama R, Asai N, Ohki M, Ohki Y, Kusubata K et al. Adipocyte-derived 
microvesicles are associated with multiple angiogenic factors and induce 
angiogenesis in vivo and in vitro. Endocrinology. 2010;151(6):2567–76. 
doi:10.1210/en.2009-1023. 
10. Muller G. Let’s shift the lipid burden- From large to small adipocytes. Eur J 
Pharmacol. 2011 Apr 10;656(1-3):1-4. doi: 10.1016/j.ejphar.2011.01.035. Epub 2011 
Feb 2. 
11. Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4); 
Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and 
Cardiovascular Disease. Clin Med Insights Cardiol. 2015 Feb 2;8(Suppl 3):23-33. 
12. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes 
Care 2015 Jan; 38(Supplement 1): S8-S16. http://dx.doi.org/10.2337/dc15-S005 
27 
 
13. Vasco F, Hawe A, Jiscoot W. Critical Evaluation of Nanoparticle Tracking Analysis 
(NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates. 
Pharm Res. 2010 May; 27(5): 796–810. 
14. Webber J, Stone TC, Katilius E, Smith BC, Gordon BE, Mason MD et al. Proteomics 
Analysis of Cancer Exosomes Using a Novel Modified Aptamer-based Array 
(SOMAscanTM) Platform. Mol Cell Proteomics. 2014 Apr; 13(4): 1050–1064. 
15. Connolly KD, Guschina IA, Yeung V, Clayton A, Draman M, von Ruhland C et al. 
Characterisation of adipocyte-derived extracellular vesicles released pre- and post-
adipogenesis. J Extracell Vesicles. 2015; 4: 10.3402/jev.v4.29159 
16. Frühbeck G, Méndez-Giménez L, Fernández-Formoso JA, Fernández S, Rodríguez A. 
Regulation of adipocyte lipolysis. Nutr Res Rev. 2014 Jun;27(1):63-93  
17. Johansson L, Ross M, Kullberg J, Weis J, Ahlstrom H, Sundbom M et al. Lipid 
mobilization following Roux-en-Y gastric bypass examined by magnetic resonance 
imaging and spectroscopy. Obes Surg. 2008 Oct;18(10):1297-304. doi: 
10.1007/s11695-008-9484-0. Epub 2008 Apr 8 
18. Karki S, Farb MG, Myers S, Apovian C, Hess DT, Gokce N. Effect of Bariatric Weight 
Loss on the Adipose Lipolytic Transcriptome in Obese Humans. Mediators Inflamm. 
2015;2015:106237. doi: 10.1155/2015/106237   
19. Furuhasi M, Matsumoto M, Hiramitsu S, Omori A, Tanaka M, Moniwa N et al. 
Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, 
28 
 
an SGLT2 Inhibitor. PLOS One. 2016 Apr 28;11(4):e0154482. doi: 
10.1371/journal.pone.0154482. eCollection 2016 
20. Comerford KB, Buchan W, Karakas SE. The Effects of Weight Loss on FABP4 and RBP4 
in Obese Women with Metabolic Syndrome. Horm Metab Res 2014; 46(03): 224-231 
DOI: 10.1055/s-0033-1353204 
21. Stejskal D, Karpisek M, Bronsky J. Serum adipocyte-fatty acid binding protein 
discriminates patients with permanent and temporary body weight loss. J Clin Lab 
Anal. 2008;22(5):380-2. doi: 10.1002/jcla.20270 
22. Campello E, Zabeo E, Radu CM, Spiezia L, Foletto M, Prevedello L et al. Dynamics of 
circulating microparticles in obesity after weight loss. Intern Emerg Med. 2016 
Aug;11(5):695-702. doi: 10.1007/s11739-016-1397-7. Epub 2016 Feb 2. 
23. Cheng V, Kashyap SR, Schauer PR, Kirwan JP, McCrae KR. Restoration of glycemic 
control in patients with type 2 diabetes mellitus after bariatric surgery is associated 
with reduction in microparticles. Surg Obes Relat Dis. 2013 Mar-Apr;9(2):207-12. 
24. Stepanian A, Bourguigant H, Hennou S, Coupaye M, Hajage D, Salomon L et al. 
Microparticle increase in severe obesity: not related to metabolic syndrome and 
unchanged after massive weight loss. Obesity (Silver Spring) 2013 Nov;21(11):2236-
43. doi: 10.1002/oby.20365. Epub 2013 Jul 2. 
25. Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. 
Nat Rev Endocrinol. 2015 Aug;11(8):465-77 
29 
 
26. Witwer KW, Buzás EI, Bemis LT et al. Standardization of sample collection, isolation 
and analysis methods in extracellular vesicle research. Journal of Extracellular 
Vesicles. 2013;2:10.3402/jev.v2i0.20360. doi:10.3402/jev.v2i0.20360. 
27. Celio AC, Wu Q, Kasten KR, Manwaring ML, Pories WJ, Spaniolas K. Comparative 
effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy in super obese 
patients. Surg Endosc. 2016 Jun 10. [Epub ahead of print] 
28. Lee SK, Heo Y, Park JM, Kim YJ, Kim SM, Park do J et al. Roux-en-Y Gastric Bypass vs. 
Sleeve Gastrectomy vs. Gastric Banding: The First Multicenter Retrospective 
Comparative Cohort Study in Obese Korean Patients. Yonsei Med J. 2016 
Jul;57(4):956-62. doi: 10.3349/ymj.2016.57.4.956 
29. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. 
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):27-33. doi: 
10.1161/ATVBAHA.110.218123.  
 
 
 
 
 
 
 
30 
 
Supplementary material- methodology 
Time resolved fluorescence immunoassay 
High affinity protein binding 96 wells plates were loaded with 5x109 EVs/well diluted to a 
total volume of 100µL with x1 filtered PBS and incubated overnight at 4˚C. Following a wash 
with Delfia Buffer (Perkin Elmer, Waltham, MA, USA), non-specific sites were blocked with 
1% (wt/vol) Bovine Serum Albumin (BSA) in PBS for 2 hours. Following a further wash, 
primary antibodies were added in duplicates at 3µg/mL concentration (anti-CD41, anti- 
CD11b, anti-CD235a, anti-CD144, anti-CD9, anti-IL-6, anti-TNFα, anti-interferon ɤ, anti-
adiponectin, anti-FABP4 and anti-PPARɤ). After overnight incubation, secondary antibody 
(anti-rabbit IgG Biotin labelled, 1:2500 in 0.1 % (wt/vol) BSA in PBS) was added, followed by 
staining with Europium-labelled Streptavidin (Perkin Elmer, Waltham, MA, USA). Delfia 
Enhancement Solution (Perkin Elmer, Waltham, MA, USA) was then added leading to 
formation of fluorescent chelates. The plate was measured using a CLARIOstar spectrometer 
(BMG Labtech Ltd, Aylesbury, UK) configured to Time Resolved Fluorescence (TRF). 
All primary rabbit monoclonal antibodies were supplied by Abcam (Cambridge, UK) apart 
from anti-CD9 antibody which was provided by Cell Signalling Technology (Danvers, AM, 
USA). For the analysis of internal EV content, RIPA Lysis Buffer (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA) containing protease inhibitor, sodium orthovanadate and 
phenylmethylsulfonyl fluoride (PMSF) was added for 1 hour before the addition of primary 
antibodies to enable the disruption of the EV membrane. 
 
